Joel Baglole

Joel Baglole

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

Is Pinterest a Buy After Its Latest Earnings?

PINS stock rallied 10% after the company delivered better-than-expected first quarter results. But can the upturn be sustained?

NVAX Stock Falls 20% as Novavax Misses Q1 Estimates

The drug maker's stock is falling sharply on news that the company missed the profit and revenue expectations of analysts.

CLOV Stock Pops 15% as Hard-Hit Clover Health Grows Revenue

The health insurance company's share price is popping on news of better-than-expected earnings and strong forward guidance.

Novavax Stock Is Too Sickly To Buy

Any hope that pharmaceutical company Novavax will gain widespread approval to bring a Covid-19 vaccine to market is now over.

PLUG Stock Dips Ahead of Q1 Earnings. 10 Things to Know.

The hydrogen fuel cell company's stock is falling ahead of it releasing its latest financial results once markets close today.